Predict your next investment

Corporate Venture
novoholdings.dk/investments/ventures

See what CB Insights has to offer

Investments

158

Portfolio Exits

56

Funds

2

Service Providers

2

About Novo Ventures

Novo Ventures, part of Novo Holdings, is a life science venture capital investor, delivering knowledge, network, and capital to companies. The firm strives to invest in companies that develop innovative drugs, medical devices and diagnostics that can potentially improve the health and welfare of people around the world.

Novo Ventures Headquarter Location

501 2nd Street Suite 300

San Francisco, California, 94107,

United States

+1 (415) 552-6686

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Novo Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Novo Ventures in 4 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

R

Rare Diseases

25 items

I

Industrial SynBio

382 items

Synthetic biology focused on replacing industrial and commercial materials.

Latest Novo Ventures News

Amolyt Pharma Raises $80M in Series B Financing

Sep 20, 2021

Amolyt Pharma , a Lyon, France and Cambridge, Mass.-based company specialized in developing therapeutic peptides for rare endocrine and related diseases, closed an $80m Series B equity financing round. The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation. The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities. Led by Thierry Abribat, Ph.D., founder, and chief executive officer, Amolyt Pharma is a clinical stage biotechnology company advancing therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its portfolio includes: AZP-3601, a long-acting PTH analog as a potential treatment of hypoparathyroidism, AZP-3813, a macrocyclic peptide growth hormone receptor antagonist for the potential treatment of acromegaly, and AZP-3404, which is undergoing indication selection work. FinSMEs 20/09/2021

Novo Ventures Investments

158 Investments

Novo Ventures has made 158 investments. Their latest investment was in InBrace as part of their Series D on September 9, 2021.

CBI Logo

Novo Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/8/2021

Series D

InBrace

$102M

No

BlackRock, Endeavour Vision, Farallon Capital Management, Marshall Wace Asset Management, MVM Partners, RTW Investments, Soleus Capital Management, venBIO, and Vivo Capital

4

5/20/2021

Series C

Numab Therapeutics

$111M

Yes

BlackRock, BVF Partners, Cormorant Asset Management, Forbion Capital Partners, HBM Partners, Octagon Capital, and RTW Investments

4

4/9/2021

Series C

Arcellx

$120M

No

New Enterprise Associates, Quan Capital, and Solasta Ventures

2

2/11/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

12/9/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/8/2021

5/20/2021

4/9/2021

2/11/2021

12/9/2020

Round

Series D

Series C

Series C

Series C

Series B

Company

InBrace

Numab Therapeutics

Arcellx

Subscribe to see more

Subscribe to see more

Amount

$102M

$111M

$120M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

BlackRock, Endeavour Vision, Farallon Capital Management, Marshall Wace Asset Management, MVM Partners, RTW Investments, Soleus Capital Management, venBIO, and Vivo Capital

BlackRock, BVF Partners, Cormorant Asset Management, Forbion Capital Partners, HBM Partners, Octagon Capital, and RTW Investments

New Enterprise Associates, Quan Capital, and Solasta Ventures

Sources

4

4

2

10

10

Novo Ventures Portfolio Exits

56 Portfolio Exits

Novo Ventures has 56 portfolio exits. Their latest portfolio exit was Cyteir Therapeutics on June 18, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/18/2021

IPO

$991

Public

1

4/26/2021

Acq - Fin

$991

3

4/9/2021

IPO

$991

Public

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/18/2021

4/26/2021

4/9/2021

00/00/0000

00/00/0000

Exit

IPO

Acq - Fin

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

1

3

1

10

10

Novo Ventures Fund History

2 Fund Histories

Novo Ventures has 2 funds, including Novo Seed.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Novo Seed

Early-Stage Venture Capital

1

REPAIR Impact Fund

Subscribe to see more

$99M

10

Closing Date

Fund

Novo Seed

REPAIR Impact Fund

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Amount

$99M

Sources

1

10

Novo Ventures Service Providers

2 Service Providers

Novo Ventures has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Subscribe to see more

Provider Type

Counsel

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Partnership data by VentureSource

Novo Ventures Team

7 Team Members

Novo Ventures has 7 team members, including current Senior Partner, Tiba Aynechi.

Name

Work History

Title

Status

Tiba Aynechi

Senior Partner

Current

Thomas Dyrberg

Senior Partner

Current

Kurt Anker Nielsen

Chief Executive Officer

Former

Henrik Gurtler

Chief Executive Officer

Former

Thorkil Kastberg Christensen

Chief Financial Officer

Former

Name

Tiba Aynechi

Thomas Dyrberg

Kurt Anker Nielsen

Henrik Gurtler

Thorkil Kastberg Christensen

Work History

Title

Senior Partner

Senior Partner

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Status

Current

Current

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.